Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 20/20 | 0.60 |
| ▸ | CCR3 | P51677 | 20/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 14/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2923912 | 0.87 | HRH1 (0.52) | HRH1CCR3KCNH2 | |
| SCHEMBL3937095 | 0.83 | HRH1 (0.55) | HRH1CCR3KCNH2 | |
| SCHEMBL5344932 | 0.83 | HRH1 (0.55) | HRH1CCR3KCNH2 | |
| SCHEMBL3939200 | 0.83 | HRH1 (0.55) | HRH1CCR3KCNH2 | |
| SCHEMBL5348492 | 0.80 | HRH1 (0.69) | HRH1CCR3KCNH2 | |
| SCHEMBL5338616 | 0.80 | HRH1 (0.69) | HRH1CCR3KCNH2 | |
| SCHEMBL3940844 | 0.79 | HRH1 (0.68) | HRH1CCR3KCNH2 | |
| SCHEMBL180334 | 0.79 | HRH1 (0.61) | HRH1CCR3KCNH2 | |
| SCHEMBL4154387 | 0.79 | HRH1 (0.61) | HRH1CCR3KCNH2 | |
| SCHEMBL5369447 | 0.78 | HRH1 (0.56) | HRH1CCR3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7956070-B2 | Piperidines as chemokine modulators (CCR) | ASTRAZENECA AB (SE) | 2011-06-07 | — | — | US | disclosed |
| EP-1478624-B1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-09-08 | — | — | EP | disclosed |
| US-7709500-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-20070054924-A1 | Novel piperidines as chemokine modulators (ccr) | ASTRAZENECA AB (SE) | 2007-03-08 | — | — | US | disclosed |
| EP-1713772-A1 | NOVEL PIPERIDINES AS CHEMOKINE MODULATORS (CCR) | AstraZeneca AB (SE) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005073192-A1 | NOVEL PIPERIDINES AS CHEMOKINE MODULATORS (CCR) | ASTRAZENECA AB (SE) | 2005-08-11 | — | — | WO | disclosed |
| US-20050107428-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107428-A1 | Chemical compounds | CCR10, CCR3, CXCR5 | HRH1 33/4885CCR3 2/4885KCNH2 862/4885 |
| US-20070054924-A1 | Novel piperidines as chemokine modulators (ccr) | CCR3, CCR1, CCR4 | HRH1 81/4885CCR3 1/4885KCNH2 2399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.